Brief: Nextcell Pharma: ProTrans Trial Meets Primary Endpoint

NextCell Pharma AB

10/12/2020 16:00

Dec 10 (Reuters) - NextCell Pharma AB  NXTCL.ST :
    * PROTRANS TRIAL MEETS PRIMARY ENDPOINT
    * NO SERIOUS ADVERSE REACTIONS WERE OBSERVED DURING 12-MONTH
FOLLOW-UP PERIOD

Source text for Eikon:  ID:nWkr1SwDLl 
Further company coverage:  NXTCL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))